Tumor-specific mutant antigen presentation via human leukocyte antigen molecule

The process described as "Tumor-specific mutant antigen presentation via HLA molecules" is not a canonical molecule or receptor, but rather a mechanism by which **mutant antigens (neoantigens) derived from tumor-specific genetic alterations are presented on the tumor cell surface by human leukocyte antigen (HLA, also known as major histocompatibility complex, MHC) molecules**. This process enables the immune system, particularly cytotoxic CD8+ T cells, to recognize and target tumor cells[1][3][6]. The proper functioning of HLA-mediated antigen presentation is essential for the efficacy of cancer immunotherapies like immune checkpoint inhibitors[4][5][6]. Tumor cells often evade immune detection by downregulating components of the antigen processing and presentation machinery (e.g., loss of HLA-I, TAP, β2-microglobulin), which is a major mechanism of resistance to immunotherapy and a challenge for treatment[4][5][6]. Restoration or enhancement of antigen presentation can reinvigorate anti-tumor responses. However, the query does not describe a discrete, druggable target such as a receptor, enzyme, or transporter, but rather a cellular process involving multiple molecular components. **Note:** This entry is not a single target but a pathway/process; therefore, 'is_incorrect' is set to true, and it should not be cataloged as a standard molecular target for drug development, although the pathway is functionally and therapeutically critical in cancer immunotherapy[4][5][6].

Other names

mutant neoantigen presentation via HLAtumor neoantigen-HLA presentationHLA-mediated neoantigen display

Enhancement of T cell recognition of tumor neoantigen–HLA complexes; Restoration of antigen presentation machinery to increase tumor immunogenicity